Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease

Virology Journal

Volumn 8, Issue , 2011, Pages

  Golden, Joseph W ^a   Zaitseva, Marina ^b   Kapnick, Senta ^b   Fisher, Robert W ^b   Mikolajczyk, Malgorzata G ^b   Ballantyne, John ^c   Golding, Hana ^b   Hooper, Jay W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c Aldevron LLC   (United States)

Author keywords

bioluminescence; DNA vaccine; monoclonal antibody; passive protection; polyclonal antibody; Smallpox; vaccinia immunoglobulin

Indexed keywords

ANTIGEN; DNA VACCINE; POLYCLONAL ANTIBODY; VIRUS ANTIBODY; HETEROPHILE ANTIBODY; SMALLPOX VACCINE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; ELECTROPORATION; ENVELOPED VIRION; EXPERIMENTAL RABBIT; FEMALE; LETHALITY; MATURE VIRION; MOUSE; NONHUMAN; ORTHOPOXVIRUS; VACCINIA; VIRION; VIRUS NEUTRALIZATION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; GENETICS; IMMUNOLOGY; MOLECULAR IMAGING; MUSCLE; RABBIT; SERODIAGNOSIS; VACCINIA VIRUS;

MONKEYPOX VIRUS; MURINAE; MUS; ORTHOPOXVIRUS; ORYCTOLAGUS CUNICULUS; PRIMATES; VACCINIA VIRUS; VARIOLA VIRUS;

ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; ELECTROPORATION; FEMALE; MICE; MICE, INBRED BALB C; MOLECULAR IMAGING; MUSCLES; NEUTRALIZATION TESTS; RABBITS; SMALLPOX VACCINE; VACCINES, DNA; VACCINIA; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRION;

EID: 80053173369     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-441     Document Type: Article

References (81)

1. Zoonotic Infections of Buffalopox in India. Bhanuprakash V, Venkatesan G, Balamurugan V, Hosamani M, Yogisharadhya R, Gandhale P, Reddy KV, Damle AS, Kher HN, Chandel BS, et al. Zoonoses Public Health 2009
2. Zoonotic poxviruses. Essbauer S, Pfeffer M, Meyer H, Vet Microbiol 2010 140 229 236 10.1016/j.vetmic.2009.08.026 19828265
3. The zoonotic poxviruses. Lewis-Jones S, Dermatol Nurs 2002 14 79 82 85-76; quiz 87 12017086
4. Buffalopox: an emerging and re-emerging zoonosis. Singh RK, Hosamani M, Balamurugan V, Bhanuprakash V, Rasool TJ, Yadav MP, Anim Health Res Rev 2007 8 105 114 10.1017/S1466252307001259 17692147
5. The detection of monkeypox in humans in the Western Hemisphere. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, Kazmierczak JJ, Stratman EJ, Li Y, Fairley JA, et al. N Engl J Med 2004 350 342 350 10.1056/NEJMoa032299 14736926 (Pubitemid 38101629)
6. Human cowpox in a veterinary student. Glatz M, Richter S, Ginter-Hanselmayer G, Aberer W, Mullegger RR, Lancet Infect Dis 2010 10 288 10.1016/S1473-3099(10)70054-2 20334852
7. Package insert. Acambis, ACAM2000 smallpox (vaccinia) vaccine, live 2008
8. Package insert. Cangene, CNJ-016 Vaccinia Immune Globulin Intravenous (human), steril solution 2009
9. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, Liu J, Gardner B, Downing G, Blum PS, et al. Int J Infect Dis 2004 8 Suppl 2 31 44 15491873
10. Adverse events occurring after smallpox vaccination. Lane JM, Goldstein J, Semin Pediatr Infect Dis 2003 14 189 195 10.1016/S1045-1870(03)00032-3 12913830 (Pubitemid 36994970)
11. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, Nichols R, Balser JP, Currie M, Monath TP, Vaccine 2005 23 3301 3309 10.1016/j.vaccine. 2005.01.079 15837236 (Pubitemid 40523124)
12. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Wittek R, Int J Infect Dis 2006 10 193 201 10.1016/j.ijid.2005.12.001 16564720
13. Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers. Hopkins RJ, Kramer WG, Blackwelder WC, Ashtekar M, Hague L, Winker-La Roche SD, Berezuk G, Smith D, Leese PT, Clin Infect Dis 2004 39 759 766 10.1086/422998 15472804 (Pubitemid 39244286)
14. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Kesson AM, Ferguson JK, Rawlinson WD, Cunningham AL, Clin Infect Dis 1997 25 911 914 10.1086/515534 9356807 (Pubitemid 27443862)
15. Progressive vaccinia successfully treated with vaccinia immune globulins. Seth V, Malaviya AN, Gopalan PR, Ghai OP, Indian Pediatr 1978 15 67 72 78892 (Pubitemid 9095822)
16. Studies smallpox and complications of smallpox vaccination. Kempe CH, Pediatrics 1960 26 176 189 14408455
17. Vaccinia gangrenosa treated with hyperimmune vaccinal gamma globulin. Barbero GJ, Gray A, Scott TF, Kempe CH, Pediatrics 1955 16 609 618 13273097
18. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Antoine G, Scheiflinger F, Dorner F, Falkner FG, Virology 1998 244 365 396 10.1006/viro.1998.9123 9601507 (Pubitemid 28384101)
19. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, et al. J Virol 2008 82 3517 3529 10.1128/JVI.01854-07 18199639 (Pubitemid 351429927)
20. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. Braxton CL, Puckett SH, Mizel SB, Lyles DS, J Virol 2010 84 3552 3561 10.1128/JVI.01572-09 20089648
21. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, Detolla LJ, Davis HL, Eisenberg RJ, Cohen GH, Isaacs SN, Vaccine 2010 28 6627 6636 10.1016/j.vaccine.2010.07.030 20659519
22. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu Y, Hirst S, Villarreal L, Felgner PL, Crotty S, J Virol 2005 79 11724 11733 10.1128/JVI.79.18.11724-11733.2005 16140750 (Pubitemid 41279291)
23. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. Demkowicz WE, Maa JS, Esteban M, J Virol 1992 66 386 398 1727494
24. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B, J Virol 2004 78 10230 10237 10.1128/JVI.78.19.10230-10237.2004 15367588 (Pubitemid 39258347)
25. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Fogg CN, Americo JL, Lustig S, Huggins JW, Smith SK, Damon I, Resch W, Earl PL, Klinman DM, Moss B, Vaccine 2007 25 2787 2799 10.1016/j.vaccine.2006.12.037 17229505 (Pubitemid 46412575)
26. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L, Virology 1999 254 71 80 10.1006/viro.1998.9516 9927575 (Pubitemid 29391715)
27. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Golden JW, Hooper JW, Virology 2008 377 19 29 10.1016/j.virol.2008.04.003 18482742
28. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Golden JW, Josleyn MD, Hooper JW, Vaccine 2008 26 3507 3515 10.1016/j.vaccine.2008.04.017 18485547
29. Subunit recombinant vaccine protects against monkeypox. Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, et al. J Immunol 2006 177 2552 2564 16888017 (Pubitemid 44201014)
30. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL, Virology 2000 266 329 339 10.1006/viro.1999.0096 10639319 (Pubitemid 30070637)
31. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Hooper JW, Custer DM, Thompson E, Virology 2003 306 181 195 10.1016/S0042-6822(02)00038-7 12620810 (Pubitemid 36293408)
32. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Hooper JW, Ferro AM, Golden JW, Silvera P, Dudek J, Alterson K, Custer M, Rivers B, Morris J, Owens G, et al. Vaccine 2009
33. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Hooper JW, Golden JW, Ferro AM, King AD, Vaccine 2007 25 1814 1823 10.1016/j.vaccine.2006.11.017 17240007 (Pubitemid 46176327)
34. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, Steffen SE, Schmaljohn CS, Schmaljohn AL, Jahrling PB, J Virol 2004 78 4433 4443 10.1128/JVI.78.9.4433-4443.2004 15078924 (Pubitemid 38501063)
35. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, et al. J Virol 2008 82 6829 6837 10.1128/JVI.00353-08 18448519 (Pubitemid 351977704)
36. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D, Vaccine 2004 22 3358 3366 10.1016/j.vaccine.2004.02.034 15308360 (Pubitemid 39078753)
37. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Sakhatskyy P, Wang S, Chou TH, Lu S, Virology 2006 355 164 174 10.1016/j.virol.2006.07.017 16919703 (Pubitemid 44692776)
38. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S, Virology 2007
39. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Xiao Y, Aldaz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, Lou H, Davis HL, Braciale TJ, Eisenberg RJ, Cohen GH, Isaacs SN, Vaccine 2007 25 1214 1224 10.1016/j.vaccine.2006.10.009 17098336 (Pubitemid 46027342)
40. The Future of Smallpox Vaccination: is MVA the key? Slifka MK, Med Immunol 2005 4 2 10.1186/1476-9433-4-2 15740619 (Pubitemid 41460814)
41. Evaluating the Orthopoxvirus type I Interferon Binding Molecule as a Vaccine Target in the Vaccinia Virus Intranasal Murine Challenge Model. Golden JW, Hooper JW, Clinical and Vaccine Immunology 2010
42. The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. Xu RH, Cohen M, Tang Y, Lazear E, Whitbeck JC, Eisenberg RJ, Cohen GH, Sigal LJ, J Exp Med 2008 205 981 992 10.1084/jem.20071854 18391063 (Pubitemid 351549892)
43. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, Martin W, De Groot AS, Vaccine 2011 29 501 511 10.1016/j.vaccine.2010.10.064 21055490
44. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA, J Virol 2004 78 7052 7060 10.1128/JVI.78.13.7052-7060.2004 15194781 (Pubitemid 38781543)
45. Improved smallpox vaccines. Isaacs SN, New Generation Vaccines New York: Informa Helthcare, evine MM, Dougan G, Good MF, Liu B, Nabel EG, Nataro JP, Rappuoli R, 4 2010 838 850
46. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. Zaitseva M, Kapnick SM, Scott J, King LR, Manischewitz J, Sirota L, Kodihalli S, Golding H, J Virol 2009 83 10437 10447 10.1128/JVI.01296-09 19656894
47. Passive Immunotherapies Protect WRvFire and IHD-J-Luc Vaccinia Virus-Infected Mice from Lethality by Reducing Viral Loads in the Upper Respiratory Tract and Internal Organs. Zaitseva M, Kapnick SM, Meseda CA, Shotwell E, King LR, Manischewitz J, Scott J, Kodihalli S, Merchlinsky M, Nielsen H, et al. J Virol 2011 85 9147 9158 10.1128/JVI.00121-11 21715493
48. Progressive vaccinia in a military smallpox vaccinee-United States, 2009. MMWR Morb Mortal Wkly Rep 2009 58 532 536 19478722
49. Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin. Fisher RW, Reed JL, Snoy PJ, Mikolajczyk MG, Bray M, Scott DE, Kennedy MC, Clin Vaccine Immunol 2011 18 67 74 10.1128/CVI.00280-10 21106779
50. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. Benhnia MR, McCausland MM, Su HP, Singh K, Hoffmann J, Davies DH, Felgner PL, Head S, Sette A, Garboczi DN, Crotty S, J Virol 2008 82 3751 3768 10.1128/JVI.02244-07 18234801 (Pubitemid 351429950)
51. Proteome-wide analysis of the serological response to vaccinia and smallpox. Davies DH, Molina DM, Wrammert J, Miller J, Hirst S, Mu Y, Pablo J, Unal B, Nakajima-Sasaki R, Liang X, et al. Proteomics 2007 7 1678 1686 10.1002/pmic.200600926 17443847 (Pubitemid 46841828)
52. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B, J Virol 2005 79 13454 13462 10.1128/JVI.79.21.13454- 13462.2005 16227266 (Pubitemid 41508158)
53. Neutralizing epitope on penetration protein of vaccinia virus. Ichihashi Y, Oie M, Virology 1996 220 491 494 10.1006/viro.1996.0337 8661400 (Pubitemid 26201703)
54. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Wolffe EJ, Vijaya S, Moss B, Virology 1995 211 53 63 10.1006/viro.1995.1378 7645236
55. Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. Rodriguez JF, Janeczko R, Esteban M, J Virol 1985 56 482 488 4057358 (Pubitemid 16192335)
56. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. Hsiao JC, Chung CS, Chang W, J Virol 1999 73 8750 8761 10482629 (Pubitemid 29441740)
57. Structural and functional characterization of a cell surface binding protein of vaccinia virus. Maa JS, Rodriguez JF, Esteban M, J Biol Chem 1990 265 1569 1577 2104847
58. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Lustig S, Fogg C, Whitbeck JC, Moss B, Virology 2004 328 30 35 10.1016/j.virol.2004.07.024 15380355 (Pubitemid 39221909)
59. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Law M, Smith GL, Virology 2001 280 132 142 10.1006/viro.2000.0750 11162827 (Pubitemid 34158059)
60. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. Vanderplasschen A, Hollinshead M, Smith GL, J Gen Virol 1997 78 Pt 8 2041 2048 9267005 (Pubitemid 27367692)
61. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. Benhnia MR, McCausland MM, Moyron J, Laudenslager J, Granger S, Rickert S, Koriazova L, Kubo R, Kato S, Crotty S, J Virol 2009 83 1201 1215 10.1128/JVI.01797-08 19019965
62. Interspecies incompatibilities of Complement Factors and Regulators. Kitamura H, The Complement System Berlin: Springer, Rother K, Till GO, Hansch GM, 5 1998 1 179 187
63. Update: multistate outbreak of monkeypox - Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003 52 642 646 12855947
64. Safety of intravenous immunoglobulin treatment. Caress JB, Kennedy BL, Eickman KD, Expert Opin Drug Saf 2010 9 971 979 10.1517/14740338.2010.484419 20408737
65. Capturing the natural diversity of the human antibody response against vaccinia virus. Lantto J, Haahr Hansen M, Rasmussen SK, Steinaa L, Poulsen TR, Duggan J, Dennis M, Naylor I, Easterbrook L, Bregenholt S, et al. J Virol 2011 85 1820 1833 10.1128/JVI.02127-10 21147924
66. Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. Benhnia MR, McCausland MM, Laudenslager J, Granger SW, Rickert S, Koriazova L, Tahara T, Kubo RT, Kato S, Crotty S, J Virol 2009 83 12355 12367 10.1128/JVI.01593-09 19793826
67. Characterization of chimpanzee/human monoclonal antibodies to the vaccinia A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia mouse protection model. Chen Z, Earl P, Americo J, Damon I, Smith SK, Yu F, Sebrell A, Emerson S, Cohen G, Eisenberg RJ, et al. J Virol 2007
68. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Chen Z, Earl P, Americo J, Damon I, Smith SK, Zhou YH, Yu F, Sebrell A, Emerson S, Cohen G, et al. Proc Natl Acad Sci USA 2006 103 1882 1887 10.1073/pnas.0510598103 16436502 (Pubitemid 43228787)
69. Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Su HP, Golden JW, Gittis AG, Hooper JW, Garboczi DN, Virology 2007
70. Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. Aldaz-Carroll L, Xiao Y, Whitbeck JC, de Leon MP, Lou H, Kim M, Yu J, Reinherz EL, Isaacs SN, Eisenberg RJ, Cohen GH, J Virol 2007 81 8131 8139 10.1128/JVI.00374-07 17522205 (Pubitemid 47101499)
71. Overview: cause and prevention in biowarfare and bioterrorism. Hilleman MR, Vaccine 2002 20 3055 3067 10.1016/S0264-410X(02)00300-6 12163257
72. Potential biological weapons threats. Kortepeter MG, Parker GW, Emerg Infect Dis 1999 5 523 527 10.3201/eid0504.990411 10458957 (Pubitemid 29418180)
73. Shining light on "Dark Winter". O'Toole T, Mair M, Inglesby TV, Clin Infect Dis 2002 34 972 983 10.1086/339909 11880964 (Pubitemid 34229767)
74. Bioterrorism: redefining prevention. Graham B, Talent J, Biosecur Bioterror 2009 7 125 126 10.1089/bsp.2009.0610 19538044
75. A new technique for obtaining whole pathogen transcriptomes from infected host tissues. Azhikina T, Skvortsov T, Radaeva T, Mardanov A, Ravin N, Apt A, Sverdlov E, Biotechniques 48 139 144
76. Plasmid DNA manufacturing technology. Carnes AE, Williams JA, Recent Pat Biotechnol 2007 1 151 166 10.2174/187220807780809436 19075838
77. Rapid-response vaccines - does DNA offer a solution? Forde GM, Nat Biotechnol 2005 23 1059 1062 10.1038/nbt0905-1059 16151391 (Pubitemid 41486383)
78. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Baumgarth N, Nat Rev Immunol 11 34 46
79. Overview, prevention, and treatment of rabies. Nigg AJ, Walker PL, Pharmacotherapy 2009 29 1182 1195 10.1592/phco.29.10.1182 19792992
80. Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Kuroiwa Y, Kasinathan P, Sathiyaseelan T, Jiao JA, Matsushita H, Sathiyaseelan J, Wu H, Mellquist J, Hammitt M, Koster J, et al. Nat Biotechnol 2009 27 173 181 10.1038/nbt.1521 19151699
81. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. Hooper JW, Ferro AM, Wahl-Jensen V, J Virol 2008 82 1332 1338 10.1128/JVI.01822-07 18032485